Efficacy and safety of long-term antibiotics (macrolides) for the treatment of chronic rhinosinusitis

Current Allergy and Asthma Reports

Volumn 14, Issue 3, 2014, Pages

  Cervin, Anders ^a   Wallwork, Ben ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Adverse effects; Airway; Antibiotics; Azithromycin; Chronic rhinosinusitis; Chronic sinusitis; Clarithromycin; Clinical trials; Efficacy; Erythromycin; Interaction; Macrolide; Mortality; Nasal polyp; Outcome; QT syndrome; Resistance; Roxithromycin; Safety; Treatment

Indexed keywords

ANTIHISTAMINIC AGENT; AZITHROMYCIN; CISAPRIDE; CLARITHROMYCIN; CYCLOSPORIN; EOSINOPHIL CATIONIC PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROLIDE; PSYCHOTROPIC AGENT; RANTES; WARFARIN; ANTIINFECTIVE AGENT;

ANTIINFLAMMATORY ACTIVITY; BRADYCARDIA; CARDIOVASCULAR DISEASE; CHRONIC RHINOSINUSITIS; COHORT ANALYSIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TRANSFORMATION; ENDOSCOPIC SINUS SURGERY; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; LONG QT SYNDROME; LONG TERM CARE; META ANALYSIS; MULTICENTER STUDY (TOPIC); NOSE OBSTRUCTION; NOSE POLYP; OPEN STUDY; OTOTOXICITY; PERCEPTION DEAFNESS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; CHRONIC DISEASE; DRUG INTERACTION; SINUSITIS;

ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; DRUG INTERACTIONS; HUMANS; MACROLIDES; SINUSITIS;

EID: 84891891540     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-013-0416-2     Document Type: Review

References (42)

1. Kudoh S, Kimura H, Uetake T, et al. Clinical effect of low-dose, long-term macrolide antibiotic chemotherapy on diffuse panbronchiolitis. Jpn J Thorac Dis. 1984;22:254-4.
2. Wallwork B, Coman W, Feron F, Mackay-Sim A, Cervin A. Clarithromycin and prednisolone inhibit cytokine production in chronic rhinosinusitis. Laryngoscope. 2002;112(10):1827-30.
3. Wallwork B, Coman W, Mackay-Sim A, Cervin A. Effect of clarithromycin on nuclear factor-kappa B and transforming growth factor-beta in chronic rhinosinusitis. Laryngoscope. 2004;114(2):286-90. (Pubitemid 38182624)
4. Suzuki H, Shimomura A, Ikeda K, Furukawa M, Oshima T, Takasaka T. Inhibitory effect of macrolides on interleukin-8 secretion from cultured human nasal epithelial cells. Laryngoscope. 1997;107(12 Pt 1):1661-6. (Pubitemid 27520179)
5. Nakajima T, Yoshizawa I, Kawano Y, Noma T. [Suppressive effect of roxithromycin on the induction of IL-2 responsiveness by DF-stimulated lymphocytes from patients with bronchial asthma]. [Japanese]. Arerugi Jpn J Allergol. 1996;45(6):554-61.
6. Ishida Y, Abe Y, Harabuchi Y. Effects of macrolides on antigen presentation and cytokine production by dendritic cells and T lymphocytes. Int J Pediatr Otorhinolaryngol. 2007;71(2):297-305. (Pubitemid 46054178)
7. Tamaoki J. The effects of macrolides on inflammatory cells. Chest. 2004;125(2 Suppl):41S-50S. quiz 1S.
8. Ishizawa K, Suzuki T, Yamaya M, Jia YX, Kobayashi S, Ida S, et al. Erythromycin increases bactericidal activity of surface liquid in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2005;289(4):L565-73. (Pubitemid 41361666)
9. Hodge S, Hodge G, Jersmann H, Matthews G, Ahern J, Holmes M, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respirator Crit Care Med. 2008;178(2):139-48. (Pubitemid 351957772)
10. Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol. 2000;14(3):143-8. (Pubitemid 30441214)
11. Wallwork B, Coman W, Mackay-Sim A, Greiff L, Cervin A. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope. 2006;116(2):189-93. (Pubitemid 44383921)
12. Haruna S, Shimada C, Ozawa M, Fukami S, Moriyama H. A study of poor responders for long-term, low-dose macrolide administration for chronic sinusitis. Rhinology. 2009;47(1):66-71.
13. Suzuki H, Ikeda K, Honma R, Gotoh S, Oshima T, Furukawa M, et al. Prognostic factors of chronic rhinosinusitis under long-term low-dose macrolide therapy. ORL J Otorhinolaryngol Relat Spec. 2000;62(3):121-7. (Pubitemid 30248562)
14. Ragab SM, Lund VJ, Scadding G. Evaluation of the medical and surgical treatment of chronic rhinosinusitis: a prospective, randomised, controlled trial. Laryngoscope. 2004;114(5):923-30. (Pubitemid 38625551)
15. Zeng M, Long XB, Cui YH, Liu Z. Comparison of efficacy of mometasone furoate versus clarithromycin in the treatment of chronic rhinosinusitis without nasal polyps in Chinese adults. Am J Rhinol Allerg. 2011;25(6):e203-7.
16. Ba L, Zhang N, Meng J, Zhang J, Lin P, Zhou P, et al. The association between bacterial colonization and inflammatory pattern in Chinese chronic rhinosinusitis patients with nasal polyps. Allergy. 2011;66(10):1296-303.
17. Jiang RS, Wu SH, Tsai CC, Li YH, Liang KL. Efficacy of Chinese herbal medicine compared with a macrolide in the treatment of chronic rhinosinusitis without nasal polyps. Am J Rhinol Allerg. 2012;26(4):293-7.
18. Luo Q, Chen F, LiuW, Li Z, Xu R, Fan Y, et al. Evaluation of long-term clarithromycin treatment in adult Chinese Patients with chronic rhinosinusitis without nasal polyps. ORL J Otorhinolaryngol Relat Spec. 2011;73(4):206-11.
19. • Majima Y, Kurono Y, Hirakawa K, Ichimura K, Haruna S, Suzaki H, et al. Efficacy of combined treatment with S-carboxymethylcysteine (carbocisteine) and clarithromycin in chronic rhinosinusitis patients without nasal polyp or with small nasal polyp. Auris Nasus Larynx. 2012;39(1):38-47. This open study has a high number of patients, n = 425 and uses the validated SNOT-20 for evaluation.
20. • Videler WJ, van Hee K, Reinartz SM, Georgalas C, van der Meulen FW, Fokkens WJ. Long-term low-dose antibiotics in recalcitrant chronic rhinosinusitis: a retrospective analysis. Rhinology. 2012;50(1):45-55. Analyses of other long-term antibiotics.
21. Nakamura Y, Suzuki M, Yokota M, Ozaki S, Ohno N, Hamajima Y, et al. Optimal duration of macrolide treatment for chronic sinusitis after endoscopic sinus surgery. Auris Nasus Larynx. 2013;40(4):366-72.
22. Cervin A, Kalm O, Sandkull P, Lindberg S. One-year low-dose erythromycin treatment of persistent chronic sinusitis after sinus surgery: clinical outcome and effects on mucociliary parameters and nasal nitric oxide. Otolaryngol-Head Neck Surg: Off J Am Acad Otolaryngol-Head Neck Surg. 2002;126(5):481-9. (Pubitemid 41123534)
23. Hashiba M, Baba S. Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol Suppl (Stockh). 1996;525:73-8. (Pubitemid 26332367)
24. Peric A, Vojvodic D, Matkovic-Jozin S. Effect of long-term, low-dose clarithromycin on T helper 2 cytokines, eosinophilic cationic protein and the 'regulated on activation, normal T cell expressed and secreted' chemokine in the nasal secretions of patients with nasal polyposis. J Laryngol Otol. 2012;126(5):495-502.
25. Dabirmoghaddam P, Mehdizadeh Seraj J, Bastaninejad S, Meighani A, Mokhtari Z. The efficacy of clarithromycin in patients with severe nasal polyposis. Acta Med Iran. 2013;51(6):359-64.
26. •• Videler WJ, Badia L, Harvey RJ, Gane S, Georgalas C, van der Meulen FW, et al. Lack of efficacy of long-term, low-dose azithromycin in chronic rhinosinusitis: a randomized controlled trial. Allergy. 2011;66(11):1457-68. One of only two placebo-controlled trials. This was a mixed group of CRS patients and no significant treatment effect was seen.
27. •• Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl. 2012;3(23):1-298. An important reference paper.
28. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper Jr JA, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-98.
29. Westphal JF. Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Brit J Clin Pharmacol. 2000;50(4):285-95.
30. Pessayre D, Larrey D, Funck-Brentano C. Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother. 1985;16(Suppl H):181-94. (Pubitemid 16246743)
31. Bachmann K, Schwartz JI, Forney Jr R, Frogameni A, Jauregui LE. The effect of erythromycin on the disposition kinetics of warfarin. Pharmacology. 1984;28(3):171-6. (Pubitemid 14161126)
32. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med. 1996;335(4):290-1.
33. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Sugawara K, et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther. 1996;59(5):514-9. (Pubitemid 26193890)
34. Cohen LG, Chesley S, Eugenio L, Flood JG, Fisch J, Goff DC. Erythromycin-induced clozapine toxic reaction. Archiv Inter Med. 1996;156(6):675-7. (Pubitemid 26095019)
35. Yee GC. Pharmacokinetic interactions between cyclosporine and other drugs. Transplant Proc. 1990;22(3):1203-7.
36. von Rosensteil NA, Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf: Int J Med Toxicol Drug Exp. 1995;13(2):105-22.
37. Yumibe N, Huie K, Chen K, Clement R, Caten M. Identification of human liver cytochrome P450s involved in the microsomal metabolism of the antihistaminic drug loratadine (Abstract). J Allergy Clin Immunol. 1994;93:234-4.
38. Patel AM, Shariff S, Bailey DG, Juurlink DN, Gandhi S, Mamdani M, et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann InterMed. 2013;158(12):869-76.
39. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881-90.
40. Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med. 2013;368(18):1665-8.
41. •• Schembri S, Williamson PA, Short PM, Singanayagam A, Akram A, Taylor J, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ. 2013;346:f1235. The most recent report in a large cohort, suggsting an increased risk of about 1.6.
42. Periti P, Mazzei T, Mini E, Novelli A. Adverse effects of macrolide antibacterials. Drug Saf: Int J Med Toxic Drug Exp. 1993;9(5):346-64. (Pubitemid 23325295)